Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Neurosci Res ; 71(6): 826-34, 2003 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-12605409

RESUMEN

Proteolipid protein (PLP) is the primary protein component of CNS myelin, yet myelin from the PLP(null) mouse has only minor ultrastructural abnormalities. Might compensation for a potentially unstable structure involve increased myelin synthesis and turnover? This was not the case; neither accumulation nor in vivo synthesis rates for the myelin-specific lipid cerebroside was altered in PLP(null) mice relative to wild-type (wt) animals. However, the yield of myelin from PLP(null) mice, assayed as levels of cerebroside, was only about 55% of wt control levels. Loss of myelin occurred during initial centrifugation of brain homogenate at 20,000g for 20 min, which is sufficient to sediment almost all myelin from wt mice. Cerebroside-containing fragments from PLP(null) mice remaining in the supernatant could be sedimented by more stringent centrifugation, 100,000g for 60 min. Both the rapidly and the more slowly sedimenting cerebroside-containing membranes banded at the 0.85/0.32 M sucrose interface of a density gradient, as did myelin from wt mice. These results suggest at least some myelin from PLP(null) mice differs from wt myelin with respect to physical stability (fragmented into smaller particles during dispersion) and/or density. Alternatively, slowly sedimenting cerebroside-containing particles could be myelin precursor membranes that, lacking PLP, were retarded in their processing toward mature myelin and thus differ from mature myelin in physical properties. If this is so, recently synthesized cerebroside should be preferentially found in these "slower-sedimenting" myelin precursor fragments. Metabolic tracer experiments showed this was not the case. We conclude that PLP(null) myelin is physically less stable and/or less dense than wt myelin.


Asunto(s)
Encéfalo/crecimiento & desarrollo , Proteína Proteolipídica de la Mielina/deficiencia , Vaina de Mielina/química , Vaina de Mielina/metabolismo , Factores de Edad , Animales , Western Blotting , Encéfalo/metabolismo , Química Encefálica , Cerebrósidos/análisis , Colesterol/análisis , Masculino , Ratones , Ratones Noqueados , Proteína Básica de Mielina/análisis , Vaina de Mielina/genética , ARN Mensajero/análisis
2.
J Neurochem ; 82(1): 126-36, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12091473

RESUMEN

Exposure of mice to the copper chelator, cuprizone, results in CNS demyelination. There is remyelination after removal of the metabolic insult. We present brain regional studies identifying corpus callosum as particularly severely affected; 65% of cerebroside is lost after 6 weeks of exposure. We examined recovery of cerebroside and ability to synthesize cerebroside and cholesterol following removal of the toxicant. The temporal pattern for concentration of myelin basic protein resembled that of cerebroside. We applied Affymetrix GeneChip technology to corpus callosum to identify temporal changes in levels of mRNAs during demyelination and remyelination. Genes coding for myelin structural components were greatly down-regulated during demyelination and up-regulated during remyelination. Genes related to microglia/macrophages appeared in a time-course (peaking at 6 weeks) correlating with phagocytosis of myelin and repair of lesions. mRNAs coding for many cytokines had peak expression at 4 weeks, compatible with intercellular signaling roles. Of interest were other genes with temporal patterns correlating with one of the three above patterns, but of function not obviously related to demyelination/remyelination. The ability to correlate gene expression with known pathophysiological events should help in elucidating further function of such genes as related to demyelination/remyelination.


Asunto(s)
Encéfalo/metabolismo , Cuprizona , Enfermedades Desmielinizantes/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Vaina de Mielina/metabolismo , Animales , Biomarcadores/análisis , Encéfalo/efectos de los fármacos , Tronco Encefálico/química , Tronco Encefálico/metabolismo , Cerebelo/química , Cerebelo/metabolismo , Cerebrósidos/análisis , Cerebrósidos/metabolismo , Quelantes , Colesterol/análisis , Colesterol/metabolismo , Cuerpo Calloso/química , Cuerpo Calloso/efectos de los fármacos , Cuerpo Calloso/metabolismo , Enfermedades Desmielinizantes/inducido químicamente , Enfermedades Desmielinizantes/genética , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Galactosiltransferasas/genética , Galactosiltransferasas/metabolismo , Perfilación de la Expresión Génica , Ratones , Ratones Endogámicos C3H , Proteína Básica de Mielina/análisis , Proteína Básica de Mielina/metabolismo , N-Acilesfingosina Galactosiltransferasa , Análisis de Secuencia por Matrices de Oligonucleótidos , ARN Mensajero/análisis , ARN Mensajero/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...